Pharma.Aero convened a global audience of industry leaders, logistics experts, and pharmaceutical manufacturers for a special Industry Briefing Webinar examining the geopolitical crisis in the Gulf and its implications for life science supply chains.
The session provided a timely platform for the Pharma.Aero community to exchange strategic insights and operational perspectives on the evolving disruption affecting global air cargo corridors and pharmaceutical logistics.
More than one hundred participants from across the international life science logistics ecosystem joined the discussion, reflecting the urgency and relevance of the topic for pharmaceutical supply chains worldwide.
Strategic Overview: Disruption to Global Air Cargo Flows
The webinar opened with an overview of the current geopolitical developments and their operational implications for global transport corridors.
Prof. Dr. Wouter Dewulf (University of Antwerp – Faculty of Business and Economics) presented a strategic analysis of the evolving situation, highlighting the critical role the Gulf region plays as a global transit hub for air cargo.
Key insights included:
• Approximately 20% of global air cargo flows are currently exposed to Middle East disruptions
• Europe–Asia trade lanes are among the most affected, due to the heavy reliance on Gulf transit hubs
• Reduced airspace access is forcing carriers to reroute flights through longer corridors, increasing operational complexity
• Air cargo capacity has been temporarily reduced, contributing to rising freight rates
While pharmaceuticals represent a relatively small share of total air cargo tonnage, they remain among the highest value and most time-critical shipments, making reliability a key concern for the sector.
Reliability Challenges for Life Science Logistics
Speakers emphasized that the current disruption is not solely a cost challenge but increasingly a reliability challenge for life science supply chains.
Longer routing, reduced transit capacity, and operational congestion across alternative corridors are placing additional pressure on temperature-sensitive and patient-critical shipments.
Despite these challenges, the sector has demonstrated strong adaptability. Freight carriers and logistics providers are rapidly adjusting network configurations and deploying alternative routing strategies to maintain supply continuity.
Industry Perspectives from Pharma and MedTech Manufacturers
The webinar also featured practical operational insights from leading life science companies, illustrating how manufacturers are responding to the evolving situation.
Industry speakers highlighted several key response strategies:
- Real-time visibility and monitoring tools
Pharmaceutical companies are increasingly relying on advanced control towers and real-time shipment visibility systems to quickly identify impacted shipments and assess risk exposure. - Rapid rerouting and alternative corridors
Companies are actively exploring alternative routes to maintain deliveries to Asia and other affected markets. - Multimodal logistics strategies
Several manufacturers are deploying air-to-road solutions, particularly when airspace restrictions limit direct connections. - Dual sourcing and contingency planning
Many companies have strengthened resilience strategies since the COVID-19 pandemic, including diversified logistics partners and alternative transport corridors.
These approaches are proving essential in maintaining the delivery of life-saving medicines and medical devices, particularly for patient-critical treatments such as oncology therapies.
Key Lessons: Resilience Requires Strategic Flexibility
A central message emerging from the discussion was the growing importance of resilience in global healthcare logistics. In today’s volatile geopolitical and economic environment, supply chains must be prepared to respond rapidly to disruptions.
For many organisations, Plan B and Plan C are no longer optional but essential components of supply chain strategy. At the same time, participants stressed the importance of continued collaboration across the life science logistics ecosystem to ensure reliable delivery of healthcare products worldwide.